Scarica l'app Stockscreener
28.96
4.47%
-1.355
Dopo l'orario di chiusura:
28.62
-0.34
-1.17%
Quince Therapeutics Inc Borsa (QNCX) Ultime notizie
Quince Therapeutics at Cantor conference: inhaled rapamycin gains traction By Investing.com - Investing.com India
Quince Therapeutics Faces Nasdaq Listing Compliance Challenges - The Globe and Mail
Should I Buy QNCX? QNCX 2026 AnalysisIntellectia AI™ - Intellectia AI
Quince Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Quince Therapeutics to Participate in September 2026 Investor Conferences - Quiver Quantitative
$Quince Therapeutics (QNCX.US)$ - Moomoo
QNCX stock holds steady as Quince Therapeutics pursues strategic alternatives - ad-hoc-news.de
Quince Therapeutics Announces Planned Presidential Leadership Transition - The Globe and Mail
Quince Therapeutics' Charles Ryan to Depart as President, Last Day Sept 8, 2026 - TradingView
Quince Therapeutics, Inc. Announces Resignation of Charles Ryan from President, Effective September 8, 2026 - marketscreener.com
Quince Therapeutics, Inc. SEC Filing (Aug 25, 2026) - Stock Titan
Quince Therapeutics forms Scientific Advisory Board to advance LAM-001 - scanx.trade
Quince (QNCX) Results at a Glance: The Available Earnings Metric Delivers a Beat; Market Move: Shares Finish 7.12% Lower in the Available RecordEarnings Seasonality - vinanet.vn
Balyasny Asset Management L.P. Initiates New Position in Quince Therapeutics Inc (QNCX) - GuruFocus
Craig-Hallum Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $68 - Moomoo
Quince (QNCX) Chart: Slides 0.90% to $34.26 at the Close; Price Setup: Price Remains Between $32.55 Support and $35.97 Resistance in the Available RecordSentiment Divergence - vinanet.vn
Craig-Hallum Initiates Coverage on Quince Therapeutics (QNCX) wi - GuruFocus
Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Addus Homecare (ADUS) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
LifeSci Capital Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Cuts Target Price to $98 - Moomoo
Quince Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
QNCX Reiterated by Cantor Fitzgerald -- Price Target Maintained at $70 - gurufocus.com
Quince Plans Shareholder Vote on Major Stock Issuance - The Globe and Mail
Form 8K Quince Therapeutics Inc For: 17 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Closes Orphai Acquisition With $115M PIPE Financing - Minichart
Quince Therapeutics plans special meeting to vote on share issuance and potential change of control - Investing.com
Quince Therapeutics to seek shareholder OK for Series C conversion, adding ~11M shares and reclassifying $6.3M warrants - TradingView
Ikarian Capital discloses 9.0% Quince Therapeutics (QNCX) ownership in Schedule 13G - Stock Titan
Nantahala Capital (QNCX) reports 0% stake in Quince Therapeutics in latest 13G/A - Stock Titan
Quince Therapeutics (QNCX) Jumps 5% to $34.04 as Bulls Target $35.74 ResistanceBlue Chip Entry Points - vinanet.vn
Quince Therapeutics (QNCX) books $39.6M loss but lifts cash to $116M - Stock Titan
Quince Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Quince Therapeutics, Inc. (NASDAQ: QNCX) Stock Price, News & Analysis - Kalkine
Quince Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cormorant Asset Management (QNCX) reports 9.99% Quince Therapeutics stake via convertibles - Stock Titan
Quince Therapeutics Q2 EPS of $(12.31) beats $(26.32) estimate - scanx.trade
Quince Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Quince Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update - TradingView
Quince Reports $75.5 Million Second Quarter Net Loss After Orphai Deal - Quiver Quantitative
QNCX: Orphai acquisition, $115M financing, and LAM-001 trial progress define a pivotal Q2 2026 - TradingView
Quince Therapeutics reports $75.5M Q2 net loss, $116M cash as of June 30, 2026 - TradingView
Quince Therapeutics Q2 net loss widens on acquisition charges - TradingView
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update - The Manila Times
Quince Adds Inhaled Rapamycin Program for Pulmonary Diseases - Stock Titan
Quince Therapeutics (QNCX): Balyasny group discloses 9.99% beneficial stake cap - Stock Titan
Quince Therapeutics (QNCX) Pushes Higher, Up 3.68% as Shares Test Key Resistance at $34.03Iron Condor Alert - Vinanet
Quince Therapeutics, Inc. expected to post a loss of $17.88 a shareEarnings Preview - TradingView
Quince Therapeutics (QNCX) updates S-3 shelf with legal opinion and $498K in costs - Stock Titan
Quince Therapeutics (QNCX) sees Squadron group report 5.6% ownership stake - Stock Titan
QNCX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Quince Therapeutics (QNCX) Climbs 6.73% to $24.96, Testing Key Resistance ZoneCall Spread Alert - vinanet.vn
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Announces Leadership Transition to Orphai Team - The Globe and Mail
Form S-3 Quince Therapeutics For: 31 July By Investing.com - Investing.com Canada
QNCX Q1 2026 Earnings: Massive EPS Beat of 57.6 Defies ExpectationsReturn On Capital - vinanet.vn
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):